AstraZeneca announced an agreement to acquire Modella AI, a Boston–based artificial intelligence startup specializing in generative and predictive modeling for drug discovery. Under the terms disclosed, AstraZeneca will bring Modella AI’s team of approximately 50 data scientists and engineers into its research division. The transaction, expected to close in the third quarter of 2026 pending regulatory clearances, includes an undisclosed upfront payment and performance‐based milestone payments tied to the development of AI‐enabled oncology candidates.

The acquisition aligns with AstraZeneca’s long‐term strategy to integrate cutting‐edge digital technologies into its R&D processes, particularly within oncology. Modella AI’s proprietary platform uses advanced deep‐learning algorithms to predict molecular interactions and optimize lead compounds, potentially reducing preclinical design cycles by up to 40%. By embedding AI‐driven target identification and virtual screening capabilities, AstraZeneca aims to accelerate candidate selection for its next‐generation cancer therapies, enhancing the productivity of its discovery pipeline.

AstraZeneca projects that incorporating Modella AI’s tools into its global R&D network will generate annualized cost savings of approximately $50 million by streamlining early‐stage programs and reducing dependence on outsourced chemistry work. The company expects to begin reporting incremental productivity metrics in its full‐year 2026 disclosures, with material contributions to pipeline advancement noted by mid‐2027. Integration costs are anticipated to be absorbed within existing R&D budgeting, with no change to AstraZeneca’s 2026 operating margin guidance.